CIK 0001023024 · Large accelerated filer
ANI PHARMACEUTICALS INC
Sign in to watch- Ticker
- ANIP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 582301143
- Phone
- 6097591810
- Business address
- 104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, NJ, 08540
- Former names
- BIOSANTE PHARMACEUTICALS INC, BEN ABRAHAM TECHNOLOGIES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,939,756
- in 9 filings, $1.9M under 10b5-1 plans
Net −$1,939,756. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-09 | Mutz Christopher HEAD OF RARE DISEASE | Sale 10b5-1 | −3,602 | $74.18 | $267K | 94,471 |
| 2026-03-07 | Mutz Christopher HEAD OF RARE DISEASE | Shares withheld for taxes 10b5-1 | −3,314 | $74.04 | $245K | 98,073 |
| 2026-03-07 | Gutwerg Ori SVP, GENERICS | Shares withheld for taxes | −3,314 | $74.04 | $245K | 81,468 |
| 2026-03-07 | Lalwani Nikhil PRESIDENT & CEO | Shares withheld for taxes | −17,060 | $74.04 | $1.3M | 404,889 |
| 2026-03-07 | CAREY STEPHEN P. SVP & CFO | Shares withheld for taxes | −5,150 | $74.04 | $381K | 180,393 |
| 2026-03-06 | Davis Krista SVP, CHIEF HR OFFICER | Sale 10b5-1 | −1,485 | $75.00 | $111K | 57,033 |
| 2026-03-06 | Mutz Christopher HEAD OF RARE DISEASE | Sale 10b5-1 | −2,121 | $74.22 | $157K | 101,387 |
| 2026-03-05 | CAREY STEPHEN P. SVP & CFO | Option exercise | +3,312 | $49.51 | $164K | 192,855 |
| 2026-03-05 | CAREY STEPHEN P. SVP & CFO | Sale | −3,312 | $75.42 | $250K | 189,543 |
| 2026-03-05 | CAREY STEPHEN P. SVP & CFO | Sale | −4,000 | $75.56 | $302K | 185,543 |
| 2026-03-05 | CAREY STEPHEN P. SVP & CFO | Option exercise · Stock Option (right to buy) | −3,312 | $49.51 | $164K | 9,938 |
| 2026-03-03 | Gutwerg Ori SVP, GENERICS | Sale | −2,060 | $76.50 | $158K | 84,782 |
| 2026-03-03 | Walsh Patrick D Director | Sale | −6,000 | $74.23 | $445K | 52,405 |
| 2026-03-02 | Mutz Christopher HEAD OF RARE DISEASE | Sale 10b5-1 | −417 | $74.00 | $31K | 103,508 |
| 2026-02-28 | Davis Krista SVP, CHIEF HR OFFICER | Shares withheld for taxes | −1,555 | $73.90 | $115K | 58,518 |
| 2026-02-28 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Shares withheld for taxes | −1,555 | $73.90 | $115K | 79,890 |
| 2026-02-28 | Gassert Chad SVP - CORP. DEV. & STRATEGY | Shares withheld for taxes | −2,221 | $73.90 | $164K | 74,916 |
| 2026-02-28 | Mutz Christopher HEAD OF RARE DISEASE | Shares withheld for taxes | −2,221 | $73.90 | $164K | 103,925 |
| 2026-02-28 | Gutwerg Ori SVP, GENERICS | Shares withheld for taxes | −2,221 | $73.90 | $164K | 86,842 |
| 2026-02-28 | Lalwani Nikhil PRESIDENT & CEO | Shares withheld for taxes | −12,217 | $73.90 | $903K | 421,949 |
Page 3 of 15 · 282 trades